AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AstraZeneca and Ionis have reported a major trial failure for their heart disease drug, Wainua. The news has led to a decline in share prices for both companies.
Coverage from Reuters, CNBC, and the Wall Street Journal emphasizes the market impact, noting that AstraZeneca stock dropped 9%. Yahoo Finance reports that Ionis (IONS) is heading toward its biggest single-day slump in over five years.
Further updates are expected as the companies address the trial miss, which CNBC described as a rare blow to the pharmaceutical powerhouse AstraZeneca.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
Which drug failed the clinical trial?
The heart disease drug named Wainua.
How did AstraZeneca's stock react?
According to CNBC, AstraZeneca stock dropped 9%.
What is the impact on Ionis stock?
Yahoo Finance reports that IONS stock is heading toward its biggest single-day slump in over five years.
Coverage (6)
- AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction Fierce Pharma · 5h ago
- IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years Yahoo Finance · 5h ago
- AstraZeneca's Wainua fails key heart disease trial, shares tumble Reuters · 5h ago
- AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial WSJ · 5h ago
- AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse CNBC · 5h ago
- AstraZeneca, Ionis report major trial failure with heart disease drug STAT · 5h ago
Topics
Related trends
Millions may be getting the wrong cholesterol test
Recent studies suggest millions may be using outdated cholesterol tests, with ApoB testing emerging as a more accurate marker for heart disease risk.
Why experts say peptides just might be the secret to reviving thinning hair
Peptides are gaining attention as a potential solution for thinning hair and general wellness, despite emerging concerns over black-market distribution.
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.
5 simple habits for heart that can actually protect your arteries and prevent plaque build up
Health experts are highlighting simple, everyday habits over supplements as the primary means to protect arteries and prevent cardiovascular disease.
Research Shows a Certain Amount of Strength Training Every Week Can Help You Live Longer
New research suggests that weekly strength training can lower the risk of heart disease, diabetes, and early death.
This 10-minute daily activity can reduce your risk of heart disease, dementia, and stroke
Recent studies highlight the potential health benefits of regular sauna use.